by Brad Kahl, MD, Thomas J. Kipps, MD, PhD, Julie M. Vose, MD, MBA
Mantle cell lymphoma (MCL) is characterized by an aggressive disease course and brief remissions in response to standard therapies. Our featured ex......READ MORE
by Caron A. Jacobson, MD, MMSc; Anita Kumar, MD; and Bijal Shah, MD, MS
Biologically targeted combinations for mantle cell lymphoma (MCL) hold promise for patients who need alternatives to standard frontline therapies. ......READ MORE
by Caron A. Jacobson, MD, MMSc; Anita Kumar, MD; and Bijal Shah, MD, MS
In mantle cell lymphoma (MCL), patients may be particularly vulnerable due to factors such as age-associated comorbidities, high-risk disease biolo......READ MORE
Patients with mantle cell lymphoma (MCL) who are asymptomatic and present indolently may be observed for a period of time prior to treatment initia......READ MORE
Treatment intensity in mantle cell lymphoma (MCL) has traditionally been guided by factors such as patient age and fitness vs frailty. While these ......READ MORE
Bruton tyrosine kinase (BTK) inhibitor therapy has transformed the management of relapsed mantle cell lymphoma (MCL). The second-generation agents ......READ MORE
